Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 11 recruiting now full pipeline

Osteoporosis: full-pipeline trial registry

11 of 87 indexed Osteoporosis trials are currently recruiting.

Corpus placement: #158 of 28,707 conditions by registered trial count.

87 US clinical trials · 11 currently recruiting · #158 of 28,707 conditions by registered trial count

Osteoporosis: 87 US clinical trials tracked, 11 recruiting.

Osteoporosis is the subject of 87 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 28 are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most active sponsor is University of Colorado, Denver, running 4 of these trials.

Enrollment posture brief

Registry condition osteoporosis

OPEN 11 | RECR 13% | LATE 28 | EARLY 21 | RANK #158 | SPON 4

Nearest open-share peer: Acute Respiratory Infection (13% recruiting · 8 trials)

Glioma54.5%Alcohol Drinking47.7%Chronic Obstructive Pulmonar33.3%End Stage Renal Disease28.4%Osteoporosis (this)13%
Open-enrollment share among volume-matched conditions near Osteoporosis

Osteoporosis lists 11 open slots (13% of 87 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Osteoporosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Osteoporosis is recruiting below its size-band peers.

    11 of 87 indexed trials (12.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Osteoporosis trials is spread across many organizations.

    University of Colorado, Denver accounts for 4 of 87 trials (4.6%). 65 distinct sponsors appear on at least one study for this condition label.

  3. Typical Osteoporosis enrolment sits around 81 participants.

    Median target enrolment is 81 among the 85 trials that report a genuine target (sentinel values excluded). 47 of those (55.3%) plan for fewer than 100 participants.

  4. Osteoporosis research is mostly interventional.

    73 interventional and 14 observational studies make up this index (83.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 111Phase 210Phase 312Phase 416

Open and recent trials

87 total, page 1 of 2

RECRUITING NA 2,634 participants

RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE

University of Alabama at Birmingham

NCT06455085

RECRUITING NA 2,000 participants

Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty

Johns Hopkins University

NCT05845021

RECRUITING NA 1,344 participants

OsteoPorotic fracTure preventION System (OPTIONS) Research Study

Brigham and Women's Hospital

NCT06731608

RECRUITING 648 participants

The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fractures

AO Foundation, AO Spine

NCT07027306

RECRUITING NA 220 participants

Synbiotic to Attenuate Resorption of the Skeleton

Hebrew SeniorLife

NCT06389539

RECRUITING Phase 4 155 participants

Preserving Geriatric Muscle With an Osteoporosis Medication

Susan L. Greenspan

NCT06118905

RECRUITING NA 120 participants

Mode of Exercise and Bone Biomarkers in Older Veterans

VA Office of Research and Development

NCT05266976

RECRUITING 100 participants

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

Bettina Mittendorfer

NCT07083557

RECRUITING Phase 3 56 participants

EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy

University of Texas Southwestern Medical Center

NCT05998863

RECRUITING Phase 4 50 participants

Combined Anabolic Therapy

Massachusetts General Hospital

NCT06558188

RECRUITING Phase 2 45 participants

Effect of Acetylcholinesterase Inhibitors on Bone Metabolism

Duke University

NCT06041789

ACTIVE NOT RECRUITING Phase 4 2,650 participants

Trial of Parkinson's And Zoledronic Acid

California Pacific Medical Center Research Institute

NCT03924414

ACTIVE NOT RECRUITING NA 190 participants

Utility of Cortical Bone Tissue Properties in the Assessment of Fracture Risk

Beth Israel Deaconess Medical Center

NCT03076034

ACTIVE NOT RECRUITING Phase 4 184 participants

Romosozumab Use to Build Skeletal Integrity

Susan L. Greenspan

NCT05058976

ACTIVE NOT RECRUITING NA 53 participants

Sickle Cell Disease (SCD) Bone Pain Study

University of California, Davis

NCT05283148

ACTIVE NOT RECRUITING Phase 4 51 participants

Comparative Antiresorptive Efficacy Discontinuation of Denosumab

Massachusetts General Hospital

NCT03623633

ACTIVE NOT RECRUITING Phase 4 45 participants

Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study

University of Alabama at Birmingham

NCT04177940

ACTIVE NOT RECRUITING Phase 4 40 participants

Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI

James J. Peters Veterans Affairs Medical Center

NCT05101018

ACTIVE NOT RECRUITING 40 participants

Skeletal Effects of Chronic Night Shift

University of Colorado, Denver

NCT05091021

ACTIVE NOT RECRUITING Phase 4 20 participants

Muscle Impact of Treating Osteoporosis

Nami Safai Haeri

NCT05666310

ACTIVE NOT RECRUITING Phase 1 10 participants

A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis

Memorial Sloan Kettering Cancer Center

NCT05775094

COMPLETED 57,073 participants

Evaluation of VLER-Indiana Health Information Exchange Demonstration Project

VA Office of Research and Development

NCT01446705

COMPLETED Phase 1 30,000 participants

Patient- and Physician-Based Osteoporosis Education

Brigham and Women's Hospital

NCT00073190

COMPLETED Phase 3 7,700 participants

HORIZON-PFT: Pivotal Fracture Trial

Novartis Pharmaceuticals

NCT00049829

COMPLETED Phase 4 4,659 participants

Improving Bone Health Among Rheumatoid Arthritis (RA) Patients on Chronic Glucocorticoids

University of Alabama at Birmingham

NCT01378689

COMPLETED NA 3,000 participants

Improving Quality With Outpatient Decision Support

Agency for Healthcare Research and Quality (AHRQ)

NCT00225628

COMPLETED Phase 3 2,456 participants

Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)

Novartis

NCT00145327

COMPLETED 2,452 participants

Ultrarunners Longitudinal TRAcking Study (ULTRA)

Stanford University

NCT02014038

COMPLETED Phase 3 1,683 participants

Open Label Extension Study of PREOS

Shire

NCT00172133

COMPLETED Phase 3 1,200 participants

Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy

GTx

NCT00129142

COMPLETED Phase 3 1,083 participants

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

Pfizer

NCT00242710

COMPLETED NA 741 participants

Yoga in the Treatment of Osteoporosis

Manhattan Physical Medicine and Rehabilitation

NCT02399176

COMPLETED 560 participants

Age Dependend Diagnostic Thresholds for Osteoporosis Bindex Ultrasonometer

Bone Index Finland

NCT01978834

COMPLETED NA 560 participants

CT-Based Modeling of Bone Micro-Architecture and Fracture-Risk in COPD

Punam K Saha

NCT03534934

COMPLETED Phase 3 452 participants

Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification

National Institute on Aging (NIA)

NCT00183001

COMPLETED 450 participants

A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00069004

COMPLETED Phase 3 450 participants

Effect of Calcium and Vitamin D on Bone Loss From the Hip

Tufts University

NCT00357643

COMPLETED Phase 3 439 participants

Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer

Alliance for Clinical Trials in Oncology

NCT00022087

COMPLETED Phase 3 428 participants

Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

Eli Lilly and Company

NCT00051558

COMPLETED Phase 2 354 participants

Calcium and Bone Mass in Young Females

Ohio State University

NCT00000402

COMPLETED NA 354 participants

Evaluation of Outcomes for Quality of Life and Activities of Daily Living for BKP in the Treatment of VCFs

Medtronic Spinal and Biologics

NCT01871519

COMPLETED Phase 2 340 participants

Osteoporosis Prevention in Preadolescent Girls

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NCT00000413

COMPLETED NA 273 participants

GIOP Prevention Among People With Rheumatoid Arthritis

University of North Carolina, Chapel Hill

NCT00609830

COMPLETED Phase 2 241 participants

Adding Phosphorus to Osteoporosis Drug Treatment

Creighton University

NCT00074711

COMPLETED Phase 1 228 participants

Improving Bone Health in Adolescent Girls: The Youth Osteoporosis and Understanding Total Health (YOUTH) Study

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NCT00067600

COMPLETED Phase 3 181 participants

A Comparison of PF708 and Forteo in Osteoporosis Patients

Pfenex

NCT03002428

COMPLETED Phase 4 110 participants

Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density

Novartis

NCT00431444

COMPLETED Phase 2 105 participants

Comparison Study of PTHrP and PTH to Treat Osteoporosis

University of Pittsburgh

NCT00853723

COMPLETED Phase 4 99 participants

Effects of DHEA/Exercise on Bone, Muscle and Balance

National Aeronautics and Space Administration (NASA)

NCT00664053

COMPLETED Phase 1 96 participants

Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects

Warner Chilcott

NCT00699777

Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 11
Phase 2 10
Phase 3 12
Phase 4 16

Named interventions

Most-linked intervention names on Osteoporosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
6 trials
Teriparatide Drug
5 trials
Romosozumab Drug
4 trials
Placebo Other
4 trials
zoledronic acid Drug
3 trials
Zoledronic Acid Drug
3 trials
Zoledronic acid Drug
3 trials
Vitamin D Drug
2 trials

US sites by state

Facility locations filed on Osteoporosis trials. A trial with sites in several states counts in each.

California 18 trials
Massachusetts 14 trials
Florida 13 trials
Colorado 13 trials
Pennsylvania 11 trials
Illinois 10 trials
New York 9 trials
Alabama 9 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Osteoporosis page

87 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Osteoporosis condition card totals 87 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.